Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Nat Med ; 9(4): 431-8, 2003 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-12612546

RESUMO

High-dose intravenous immunoglobulin (IVIG) prevents immune damage by scavenging complement fragments C3b and C4b. We tested the hypothesis that exogenous immunoglobulin molecules also bind anaphylatoxins C3a and C5a, thereby neutralizing their pro-inflammatory effects. Single-cell calcium measurements in HMC-1 human mast cells showed that a rise in intracellular calcium caused by C3a and C5a was inhibited in a concentration-dependent manner by IVIG, F(ab)2-IVIG and irrelevant human monoclonal antibody. C3a- and C5a-induced thromboxane (TXB2) generation and histamine release from HMC-1 cells and whole-blood basophils were also suppressed by exogenous immunoglobulins. In a mouse model of asthma, immunoglobulin treatment reduced cellular migration to the lung. Lethal C5a-mediated circulatory collapse in pigs was prevented by pretreatment with F(ab)2-IVIG. Molecular modeling, surface plasmon resonance (SPR) and western blot analyses suggested a physical association between anaphylatoxins and the constant region of F(ab)2. This binding could interfere with the role of C3a and C5a in inflammation.


Assuntos
Complemento C3a/antagonistas & inibidores , Complemento C5a/antagonistas & inibidores , Imunoglobulinas Intravenosas/farmacologia , gama-Globulinas/farmacologia , Animais , Asma/metabolismo , Pressão Sanguínea/efeitos dos fármacos , Cálcio , Linhagem Celular , Inibição de Migração Celular , Complemento C3a/metabolismo , Complemento C5a/metabolismo , Relação Dose-Resposta a Droga , Liberação de Histamina/efeitos dos fármacos , Humanos , Mastócitos/metabolismo , Camundongos , Síndrome do Desconforto Respiratório/prevenção & controle , Suínos , Tromboxano B2/metabolismo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA